{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:17:00Z","timestamp":1772165820907,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Schizophrenia is a serious mental illness, the pharmacological treatment of which comprises primarily the use of antipsychotics. However, non-adherence to their use and its reliable determination present a serious clinical and economic problem. This study aimed to determine therapeutic adherence in outpatients with schizophrenia spectrum disorders by combining short-term electronic monitoring of dispenser opening with the measurement of antipsychotic blood concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 55 patients underwent a week-long electronic monitoring of dispenser opening and measurement of blood concentrations before and after monitoring. Patients who correctly opened the dispenser at least in 80% of scheduled time points during the weekly interval and, at the same time, did not show a change in blood concentration of the antipsychotic by more than 30% in any direction, were considered adherent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>69.1% of the patients met the adherence criteria, which was less than that determined by the Drug Attitude Inventory (DAI-10), the Visual Analogue Scale (VAS), and the Clinician Rating Scale (CRS). 7.3% of the patients took less than 80% of the prescribed doses and a change in blood concentrations of the antipsychotic by more than 30% was detected in 25.4% of the patients. In 70.9% of patients, the detected concentrations were within the recommended therapeutic reference interval. The groups of adherent and non-adherent patients did not differ statistically significantly in the severity of their illness as determined by the Clinical Global Impression (CGI), the Personal and Social Performance scale (PSP), and the Positive and Negative Syndrome Scale (PANSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combined method of evaluating adherence in schizophrenia patients confirmed the results determined by other methods. The benefits of this approach are described in the paper.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-025-06981-3","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T09:33:25Z","timestamp":1747906405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of combined remote electronic monitoring and blood concentrations of antipsychotics for assessment of therapeutic adherence in patients with schizophrenia: results of a prospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Petr","family":"\u0160ilh\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"H\u00fd\u017ea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Ambro\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Dost\u00e1lek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Schwarzov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Sk\u0159ont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denisa","family":"Perni\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavla","family":"Baarov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Augustynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Kac\u00ed\u0159ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romana","family":"U\u0159inovsk\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"10202","key":"6981_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet Lond Engl. 2019;394(10202):939\u201351.","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"6981_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1192\/bjp.bp.116.186007","volume":"211","author":"H Takeuchi","year":"2017","unstructured":"Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry J Ment Sci. 2017;211(3):137\u201343.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"7","key":"6981_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, Meht\u00e4l\u00e4 J, Hoti F, Jedenius E, et al. Real-World effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686\u201393.","journal-title":"JAMA Psychiatry"},{"issue":"Suppl 4","key":"6981_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346. quiz 47\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"6981_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"key":"6981_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adherence"},{"key":"6981_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.schres.2017.06.026","volume":"193","author":"D Misdrahi","year":"2018","unstructured":"Misdrahi D, Tessier A, Husky M, Lange AC, Vrijens B, Llorca PM, et al. Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS\u00ae): A six-month post-discharge prospective study. Schizophr Res. 2018;193:114\u20138.","journal-title":"Schizophr Res"},{"key":"6981_CR8","doi-asserted-by":"publisher","unstructured":"Sacchetti E, Vita A. Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors. In: Sacchetti E, Vita A, Siracusano A, Fleischhacker W, editors. Adherence to Antipsychotics in Schizophrenia [Internet]. Milano: Springer Milan; 2014 [cited 2024 Apr 7]. pp. 1\u201384. Available from: https:\/\/doi.org\/10.1007\/978-88-470-2679-7_1","DOI":"10.1007\/978-88-470-2679-7_1"},{"key":"6981_CR9","unstructured":"Sabat\u00e9 EWHO. Adherence to Long-Term Therapies: Evidence for Action, 2003 - PAHO\/WHO| Pan American Health Organization [Internet]. World Health Organization; 2003 [cited 2024 Apr 7]. Available from: https:\/\/www.paho.org\/en\/documents\/who-adherence-long-term-therapies-evidence-action-2003"},{"issue":"4","key":"6981_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/NMD.0b013e31816a4346","volume":"196","author":"MJ Kikkert","year":"2008","unstructured":"Kikkert MJ, Barbui C, Koeter MWJ, David AS, Leese M, Tansella M, et al. Assessment of medication adherence in patients with schizophrenia: the Achilles heel of adherence research. J Nerv Ment Dis. 2008;196(4):274\u201381.","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"6981_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40263-020-00713-9","volume":"34","author":"H Yaegashi","year":"2020","unstructured":"Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and Meta-analysis. CNS Drugs. 2020;34(6):579\u201398.","journal-title":"CNS Drugs"},{"issue":"4","key":"6981_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/schbul\/sbj075","volume":"32","author":"DI Velligan","year":"2006","unstructured":"Velligan DI, Lam YWF, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724\u201342.","journal-title":"Schizophr Bull"},{"issue":"1","key":"6981_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177\u201383.","journal-title":"Psychol Med"},{"key":"6981_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1192\/bjp.172.5.413","volume":"172","author":"R Kemp","year":"1998","unstructured":"Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry J Ment Sci. 1998;172:413\u20139.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"2","key":"6981_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"issue":"4","key":"6981_CR16","first-page":"323","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"6981_CR17","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. Rev. 1976. Rockville, Md: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. 603 p."},{"key":"6981_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jchromb.2012.09.009","volume":"907","author":"R U\u0159inovsk\u00e1","year":"2012","unstructured":"U\u0159inovsk\u00e1 R, Brozmanov\u00e1 H, Si\u0161t\u00edk P, Silh\u00e1n P, Kac\u00ed\u0159ov\u00e1 I, Lemr K, et al. Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;907:101\u20137.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1\u201302","key":"6981_CR19","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"6981_CR20","unstructured":"Lieberman E, by JA MD, Stroup TS, Perkins MPH, Dixon DO. and LB. The American Psychiatric Association Publishing Textbook of Schizophrenia. Revised edition. Lieberman JA, Dixon LB, editors. Washington, D.C: Amer Psychiatric Pub Inc; 2019. 320 p."},{"issue":"Suppl 5","key":"6981_CR21","first-page":"3","volume":"67","author":"S Leucht","year":"2006","unstructured":"Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"6981_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1176\/ps.2007.58.9.1187","volume":"58","author":"DI Velligan","year":"2007","unstructured":"Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv Wash DC. 2007;58(9):1187\u201392.","journal-title":"Psychiatr Serv Wash DC"},{"issue":"1\u20133","key":"6981_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","volume":"90","author":"G Remington","year":"2007","unstructured":"Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007;90(1\u20133):229\u201337.","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"6981_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.schres.2011.11.008","volume":"134","author":"J Yang","year":"2012","unstructured":"Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134(2\u20133):226\u201331.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"6981_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.schres.2013.02.016","volume":"146","author":"FJ Acosta","year":"2013","unstructured":"Acosta FJ, Ramallo-Fari\u00f1a Y, Bosch E, Mayans T, Rodr\u00edguez CJ, Caravaca A. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS\u00ae). Schizophr Res. 2013;146(1\u20133):196\u2013200.","journal-title":"Schizophr Res"},{"issue":"2","key":"6981_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.euroneuro.2013.11.013","volume":"24","author":"C Brain","year":"2014","unstructured":"Brain C, Sameby B, Allerby K, Lindstr\u00f6m E, Eberhard J, Burns T, et al. Twelve months of electronic monitoring (MEMS\u00ae) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2014;24(2):215\u201322.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"issue":"1\u20132","key":"6981_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","volume":"225","author":"KV Sendt","year":"2015","unstructured":"Sendt KV, Tracy DK, Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015;225(1\u20132):14\u201330.","journal-title":"Psychiatry Res"},{"issue":"6","key":"6981_CR28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.clinthera.2007.06.013","volume":"29","author":"M Yang","year":"2007","unstructured":"Yang M, Barner JC, Worchel J. Factors related to antipsychotic oversupply among central Texas veterans. Clin Ther. 2007;29(6):1214\u201325.","journal-title":"Clin Ther"},{"issue":"8","key":"6981_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00005650-200208000-00002","volume":"40","author":"M Valenstein","year":"2002","unstructured":"Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630\u20139.","journal-title":"Med Care"},{"issue":"2","key":"6981_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1055\/s-0044-101838","volume":"52","author":"P Silhan","year":"2019","unstructured":"Silhan P, Urinovska R, Kacirova I, Hyza M, Grundmann M, Ceskova E. What does antidepressant drug level monitoring reveal about outpatient treatment and patient adherence?? Pharmacopsychiatry. 2019;52(2):78\u201383.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"6981_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, et al. Real-World evidence of the clinical and economic impact of Long-Acting injectable versus oral antipsychotics among patients with schizophrenia in the united States: A systematic review and Meta-Analysis. CNS Drugs. 2021;35(5):469\u201381.","journal-title":"CNS Drugs"},{"issue":"1","key":"6981_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/schbul\/sbab087","volume":"48","author":"M Solmi","year":"2022","unstructured":"Solmi M, Tiihonen J, L\u00e4hteenvuo M, Tanskanen A, Correll CU, Taipale H. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. Schizophr Bull. 2022;48(1):166\u201375.","journal-title":"Schizophr Bull"},{"key":"6981_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/NDT.S395383","volume":"19","author":"R Milz","year":"2023","unstructured":"Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, et al. The effect of longer dosing intervals for Long-Acting injectable antipsychotics on outcomes in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:531\u201345.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"6981_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5271\/sjweh.555","volume":"26","author":"G Wickstr\u00f6m","year":"2000","unstructured":"Wickstr\u00f6m G, Bendix T. The Hawthorne effect--what did the original Hawthorne studies actually show? Scand J Work Environ Health. 2000;26(4):363\u20137.","journal-title":"Scand J Work Environ Health"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06981-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06981-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06981-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T09:33:30Z","timestamp":1747906410000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06981-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6981"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06981-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4322437\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the University Hospital Ostrava, reference number 399\/2017. All the participants signed the informed consent with participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"523"}}